Strong commercial momentum with Avmapki generating exceptional revenue growth (1,095% YoY), expanding pipeline with VS-7375 showing encouraging early data across multiple cancer types, and near-term catalysts expected in October 2026 with potential phase III pivotal trial initiation in H1 2027.
Articles that tag VSTM but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
